Fragment based Drug Discovery

Fragment-based drug discovery (FBDD) represents a pivotal shift in the approach to developing new therapeutic agents, offering a streamlined and rational strategy for identifying potent drug candidates. At its core, FBDD harnesses the power of small, low molecular-weight compounds known as fragments to explore the binding interactions between these fragments and biological targets. These fragments typically consist of simple chemical structures, often comprising fewer than 20 non-hydrogen atoms, and are chosen based on their diverse chemical properties and ability to interact with specific regions of a target protein.

In FBDD, the screening process begins with the identification of a library of fragment compounds, which may range from hundreds to thousands in number. These fragments are then screened using biophysical techniques such as nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, surface plasmon resonance (SPR), or thermal shift assays to elucidate their binding affinity and mode of interaction with the target protein. Unlike traditional high-throughput screening methods, FBDD focuses on the detection of weak binding interactions, often in the millimolar to micromolar range, allowing for the identification of fragments that possess desirable binding properties despite their low affinity.

Once initial fragment hits have been identified, medicinal chemists employ a variety of strategies to optimize their binding affinity, specificity, and drug-like properties. This process, known as fragment elaboration or optimization, involves iteratively growing or linking fragments together to enhance their potency while maintaining favorable physicochemical properties such as solubility, permeability, and metabolic stability. Structural information obtained from X-ray crystallography or NMR spectroscopy is instrumental in guiding these optimization efforts, providing valuable insights into the binding interactions between fragments and the target protein.